Iguratimod is a Small Molecule owned by FUJIFILM Toyama Chemical, and is involved in 3 clinical trials, which were completed.

Iguratimod is a selective inhibitor of cyclo-oxygenase-2 (COX-2), and inhibits the production of interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis factor. The joint targeted effector mechanism of the classical model is probably quite complex, involving T-cell stimulation of synovial cells, T-cell independent mesenchymal activation, and an arthritogenic effect in which antibodies bind to cartilage. The proinflammatory cytokines, mainly TNF-a, IL-1beta and IL-6, are considered powerful targets in the treatment of RA. Iguratimod could reduce immunoglobulin production by acting directly on B lymphocytes in both mice and humans, despite having no notable action on B-lymphocyte proliferation. Methotrexate is an antimetabolite. It interferes with the way cells utilize essential nutrients. As a result, methotrexate inhibits the activity of the immune system, consequently reducing inflammation. The drug candidate further acts by suppression of nuclear factor kappa B (NF-kB) activation without blocking NF-kB inhibitor a (IkBa) degradation thereby suppresses lymphocyte proliferation, immunoglobulin production and production of inflammatory cytokines. As a cytotoxic drug it may slow the rapid growth of cells in the synovial membrane that lines the joints.

The revenue for Iguratimod is expected to reach a total of $307m through 2036. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Iguratimod NPV Report.

Iguratimod is originated and owned by FUJIFILM Toyama Chemical. Eisai is the other company associated in development or marketing of Iguratimod.

Iguratimod Overview

Iguratimod (Kolbet, Careram) is a methane-sulfonanilide derivative acts as disease- modifying anti-rheumatic agent. It is formulated as film coated tablets for oral route of administration. It is indicated for the treatment of rheumatoid arthritis.

It was also under development for the treatment of rheumatoid arthritis in South Korea and South Africa.

Eisai Overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY756,226 million for the fiscal year ended March 2022 (FY2022), an increase of 17.1% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 8% in FY2021. In FY2022, the company recorded a net margin of 6.3%, compared to a net margin of 6.5% in FY2021. The company reported revenues of JPY174,364 million for the second quarter ended September 2022, a decrease of 5.4% over the previous quarter.

Quick View – Iguratimod

Report Segments
  • Innovator (NME)
Drug Name
  • Iguratimod
Administration Pathway
  • Oral
Therapeutic Areas
  • Immunology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.